Clearmind Secures Patent for Obesity and Fatty Liver Disease Therapy
Event summary
- Clearmind Medicine published an international patent for a novel combination therapy targeting weight loss and fatty liver disease (MASLD).
- The therapy combines Clearmind’s proprietary MEAI with Palmitoylethanolamide (PEA) from NeuroThera Labs.
- The global weight loss drugs market is projected to reach $226 billion by 2035, up from $37 billion in 2025.
- Clearmind aims to position the therapy as a safer and more cost-effective alternative to GLP-1 agonists.
The big picture
Clearmind’s patent highlights its strategic pivot toward metabolic health, tapping into a $226 billion market by 2035. The move comes as demand for non-GLP-1 alternatives grows, positioning Clearmind to compete with established players in obesity and liver disease treatment.
What we're watching
- Market Positioning
- How Clearmind will differentiate its therapy in a rapidly growing but competitive obesity and liver health market.
- Regulatory Approval
- The pace at which the therapy advances through clinical trials and secures regulatory approvals.
- Commercialization Strategy
- Whether Clearmind can effectively partner or commercialize the therapy to capture market share.
Related topics